Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Inhibitors & Agonists-Cytoskeleton/Cell Adhesion Molecules-Selectin

Request The Product List ofSelectin Selectin

Cat. No. Product Name CAS No. Information
H2427

Rivipansel sodium

 		1189037-60-2

Rivipansel sodium (GMI-1070, PF-06460031)is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.
H2426

PSI-421

 		1067186-56-4

A potent, orally bioavailable P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
H2425

HMCEF

 		2002363-68-8

A novel P-selectin inhibitor that directly binds to P-selectin; intercalates into calf thymus DNA, cuts off DNA pBR22 and inhibits the proliferation of cancer cells; dose dependently inhibits inflammatory response of mice and inhibits thrombosis and inflammation, decreases serum TNFα and IL-8.
H2424

GMI-1271

 		1914993-95-5

A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM; weakly inhibits L-selectin (IC50=2.9 uM) and >10 uM for P-selectin; not only mobilizes AML cells out of protective niches but also blocks NF-kB activation and prevents this E-selectin-mediated chemoresistance, thereby enhancing the therapeutic effects of standard chemotherapy; also overcomes MM metastasis and chemoresistance.
H2421

GMI-1070

 		927881-99-0

GMI-1070 (Rivipansel, PF-06460031)is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1